Renflexis, Biosimilar for Remicade to Treat Crohn’s and UC, Approved by FDA

Renflexis, Biosimilar for Remicade to Treat Crohn’s and UC, Approved by FDA
Renflexis (infliximab-abda), a biosimilar of Remicade (infliximab), has been approved in the U.S. to treat a number of autoimmune diseases, including adult and pediatric Crohn’s disease and adult ulcerative colitis. Samsung Bioepis, which manufactures Renflexis, announced the U.S. Food and Drug Administration's approval notice in a recent press release. The treatment was approved for use in Europe and Australia last year. Renflexis is the first  biosimilar (cheaper biological medicines almost identical to original brand-name products) by the company to receive FDA approval. In addition to Crohn's and ulcerative colitis
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *